

Transperineal Targeted Microwave Ablation (TMA) of localized prostate cancer guided by MRI-Ultrasound fusion and organ based tracking: a pilot study

PETER KA-FUNG CHIU ET AL., NATURE PROSTATE CANCER AND PROSTATIC DISEASE, JULY 2022, PRINCE OF WALES HOSPITAL - HONG KONG

PATIENTS


lesions to be treated
23


patients
15



- Age : 45 - 75 years old
- Low to intermediate-risk PCa: ISUP 1 - 2 / Gleason 6 or 7
- PSA < 20ng/mL
- Lesion size ≤ 15 mm

METHODS



17G Needle / VLL Microwave
Energy: 12W / 2-5 min



Dedicated TMA software to
plan and guide transperineal
ablations



Koelis Trinity® with OBT
Fusion® guidance



MRI and "2nd Look" follow-up
fusion biopsy at 6 months
post-treatment



Koelis Trinity® System

RESULTS

Primary endpoint

- **21/23 (91.3%)** targets free of cancer on follow-up biopsy at 6 months



Secondary endpoints

- Urinary symptoms, uroflowmetry, erectile function, and quality of life scores had **no significant difference** at 6 months



- Median operating time **75 minutes**



- **No grade 2** or more adverse event (CTCAE classification)



KEY TAKE AWAY

- First published data on a monocentric Phase II **efficacy and safety** trial evaluating **transperineal TMA** (Targeted Microwave Ablation) on low-to-intermediate risk prostate cancer
- **TMA with Koelis OBT Fusion®** guidance is effective, safe, accurate and easy to deliver